Ticker

Quoin Pharmaceuticals (NASDAQ: QNRX) receives FDA IND clearance for a Phase 2 study of QRX003 in Peeling Skin Syndrome, with initiation expected in 2H 2026

ASHBURN, Va., June 30, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.

QRX003 Holds Orphan Drug Designation in the United States, the European Union, and Japan, Plus Fast Track and Rare Pediatric Disease Designations from the FDA Pivotal Phase 3 Study Expected to Initiate in the Second Half of 2026, with Potential NDA Filing in 2027 Positive Clinical Update from Ongoing Pediatric Compassionate Use Program Released on June 16 QRX003 Remains on Track to Potentially Become the First…

Supports Quoin's planned direct commercialization of QRX003 in Japan, one of its three core commercial territories Follows recent grant of Orphan Drug Designation to QRX003 by Japan's MHLW ASHBURN, Va., June 18, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.

Four of Six Patients Participating in the Compassionate Use Program Were Classified as ‘Improved' or ‘Significantly Improved' from Baseline Assessment Across Key Clinical Endpoints All Six Patients Are Younger than 10 Years of Age, with the Youngest Being Just 6 Months Old Duration of Treatment To-Date Ranges from 3 Weeks to 15 Months No Treatment Related Adverse Events Reported for All Six Patients Additional…